Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026

Reuters02-28

Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026

Celldex Therapeutics Inc. reported additional data from completed Phase 2 trials of barzolvolimab in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism. The company said sustained off-treatment efficacy was observed in chronic spontaneous urticaria after 52 weeks of treatment, with some patients maintaining well-controlled disease and complete response at Week 76, and that quality-of-life and angioedema measures improved in this subset. In the Phase 2 cold urticaria and symptomatic dermographism study, Celldex reported urticaria control and quality-of-life outcomes through Week 20, including complete response rates at Weeks 12 and 20. The results were presented at the AAAAI 2026 Annual Meeting on Feb. 27, 2026, and Celldex also noted that enrollment is complete in its global Phase 3 chronic spontaneous urticaria program and ongoing in its Phase 3 cold urticaria and symptomatic dermographism study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602271445PRIMZONEFULLFEED9662862) on February 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614861705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 03:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614861705","market":"nz","top_or_hot":-1,"title":"Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported additional data from completed Phase 2 trials of barzolvolimab in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism. The company said sustained off-treatment efficacy was observed in chronic spontaneous urticaria after 52 weeks of treatment, with some patients maintaining well-controlled disease and complete response at Week 76, and that quality-of-life and angioedema measures improved in this subset. In the Phase 2 cold urticaria and symptomatic dermographism study, Celldex reported urticaria control and quality-of-life outcomes through Week 20, including complete response rates at Weeks 12 and 20. The results were presented at the AAAAI 2026 Annual Meeting on Feb. 27, 2026, and Celldex also noted that enrollment is complete in its global Phase 3 chronic spontaneous urticaria program and ongoing in its Phase 3 cold urticaria and symptomatic dermographism study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602271445PRIMZONEFULLFEED9662862) on February 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-28 03:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported additional data from completed Phase 2 trials of barzolvolimab in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism. The company said sustained off-treatment efficacy was observed in chronic spontaneous urticaria after 52 weeks of treatment, with some patients maintaining well-controlled disease and complete response at Week 76, and that quality-of-life and angioedema measures improved in this subset. In the Phase 2 cold urticaria and symptomatic dermographism study, Celldex reported urticaria control and quality-of-life outcomes through Week 20, including complete response rates at Weeks 12 and 20. The results were presented at the AAAAI 2026 Annual Meeting on Feb. 27, 2026, and Celldex also noted that enrollment is complete in its global Phase 3 chronic spontaneous urticaria program and ongoing in its Phase 3 cold urticaria and symptomatic dermographism study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602271445PRIMZONEFULLFEED9662862) on February 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL3xYb0p:1","article_id":"2614861705","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614861705","pubTimestamp":1772221517,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Celldex Therapeutics Inc. reported additional data from completed Phase 2 trials of barzolvolimab in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism. The company said sustained off-treatment efficacy was observed in chronic spontaneous urticaria after 52 weeks of treatment, with some patients maintaining well-controlled disease and complete response at Week 76, and that quality-of-life and angioedema measures improved in this subset. In the Phase 2 cold urticaria and symptomatic dermographism study, Celldex reported urticaria control and quality-of-life outcomes through Week 20, including complete response rates at Weeks 12 and 20. The results were presented at the AAAAI 2026 Annual Meeting on Feb. 27, 2026, and Celldex also noted that enrollment is complete in its global Phase 3 chronic spontaneous urticaria program and ongoing in its Phase 3 cold urticaria and symptomatic dermographism study.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","CLDX":"塞德斯医疗","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技"},"translate_title":"Celldex在AAAAI 2026上报告barzolvolimab治疗慢性荨麻疹的积极2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":0.9,"NDAQ":0.9},"content_text":"Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026\n    \n\n        Celldex Therapeutics Inc. reported additional data from completed Phase 2 trials of barzolvolimab in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism. The company said sustained off-treatment efficacy was observed in chronic spontaneous urticaria after 52 weeks of treatment, with some patients maintaining well-controlled disease and complete response at Week 76, and that quality-of-life and angioedema measures improved in this subset. In the Phase 2 cold urticaria and symptomatic dermographism study, Celldex reported urticaria control and quality-of-life outcomes through Week 20, including complete response rates at Weeks 12 and 20. The results were presented at the AAAAI 2026 Annual Meeting on Feb. 27, 2026, and Celldex also noted that enrollment is complete in its global Phase 3 chronic spontaneous urticaria program and ongoing in its Phase 3 cold urticaria and symptomatic dermographism study.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602271445PRIMZONEFULLFEED9662862) on February 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614861705","isCrawlerRequest":true}